Clinical Research On Rosiglitazone And Insulin Pupm Combination Therapy Intensififd On Type2Diabetes Mellitus

Background:It was found that pancreatic islet function was about50%of normal as well as insulin resistance had presented at80%patients at the time of diagnosis of type2diabetes mellitus(T2DM). β-cell dysfunction and insulin resistance are internecine as a vicious cycle. Glucose toxicity and lipotoxicity play a key role as the chief acquired causation in this cycle by oxidative stress mechanism. The results of our previous study suggest that in newly diagnosed patients, short—term intensive insulin therapies by CSII could improve β-cell function and alleviate insulin resistance by eliminating glucotoxicity and lipotoxicity. But almost half of patients didn’t respond well to the treatment. Objective:To evaluate the effect of rosiglitazone combined with continuous subcutaneous insulin infusion (CSII) to Newly diagnosed patients with type2diabeticMethods:60Newly diagnosed patients with type2diabetes were divided into2groups randomly:rosiglitazone combined with CSII (n=30); simple CSII (n=30).The levels of blood glucose, Insulin resistance, and function of B cell were compared among them before and after2weeks of treatment. Patients in rosiglitazone combined with CSII kept accepting the treatment for12months.Results:After treatment, the blood glucose were decreased obviously. The area under the curves(AUC) of in serum insulin and C-peptide of Post Glucose-load were increased, and the insulin resistance index (Homa-IR) were low down, insulin saitivity index (ISI) were increased in both two groups. Compared with simple CSII, patients in group CSⅡ+rosiglitazone got much better Fasting glucose(FG), levels of Fasting insulin (FINS) and C-p were both decreased, AUCs were increased more obviously, the descent of Homa-IR and accrescence of ISI were significant with less insulin dose.Conclusion: Rosiglitazone combined with CSII can improve functions of B cell and insulin resistance obviously.